Didanosine

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that the American Journal of Human Genetics published peer-reviewed research from the Seqfirst-neo study conducted in partnership with Seattle Children’s and the University of Washington. Seqfirst-neo is a pioneering study focused on the application of rGS in NICU settings to improve access to a genetic diagnosis overall and specifically in underserved communities to reduce missed diagnoses and improve clinical outcomes for patients. Seqfirst-neo is the first study to use exclusion, rather than inclusion, criteria for which infants should receive genomic testing in the NICU, setting a new standard of care by enabling neonatologists to more easily identify patients to receive testing, and expanding access to patients who previously would not have been offered testing. Infants were eligible to receive rGS unless their clinical findings were fully explained by birth/physical trauma, complications of prematurity, infection or a pre-existing precise genetic diagnosis (PrGD). Findings from the study show that applying simple exclusion criteria significantly increase the number of infants in the NICU receiving a diagnosis, shorten the time to diagnosis, and drove more equitable access for diverse populations who otherwise would have not received testing. The findings further prove that expanding access to genetic testing dramatically increases the rate of a PrGD, enhances healthcare equity and reduces missed diagnoses. “There is a critical gap in our current approach to neonatal care – too many critically ill infants and newborns, particularly from underrepresented populations are not being offered genetic testing leading to missed diagnoses and opportunities for precision care,” said Mike Bamshad, MD, FACMG, Professor of Pediatrics at the University of Washington School of Medicine and Clinical Genetics Division Chief at Seattle Children’s. “Our findings showcase that by shifting today’s standard of care to an exclusion-based model for genomic testing, we can significantly expand access, improve health outcomes, and ensure that more families receive the answers they need at the most critical times.” “Seqfirst-neo’s findings have had a major impact on the way we deliver genetics services in the inpatient setting. Since implementing exclusion-based identification, we are diagnosing more infants than ever before with genetic conditions in the Seattle Children’s Hospital NICU,” said Tara Wenger, MD, PhD, FACMG, Professor of Pediatrics at the University of Washington School of Medicine and Associate Medical Director, Inpatient Service at Seattle Children’s. “By offering genetic testing at the first unexplained issue in critically ill newborns, we have an opportunity to make diagnoses before they are old enough to experience many of the complications of their genetic disorder. This allows neonatologists and other health care providers the opportunity to introduce the most precise treatments as early as possible.” Seqfirst-neo’s findings suggest that at least 60% of Level IV NICU infants should be receiving rGS. With approximately 400,000 newborn admissions annually across 800 U.S. NICUs, tens of thousands of infants with genetic conditions are likely being undiagnosed due to lack of access to testing. Additional findings from the study: The study evaluated 408 infants in the NICU, of whom 59% met eligibility criteria for rGS. Of those eligible, 126 infants were enrolled in the interventional group (IG) and received rGS, while others followed current diagnostic workflow protocols. Nearly half (49.2%) of infants in the IG received a precise genetic diagnosis (PrGD)  — an unexpectedly high yield despite broad testing criteria, compared to conventional care (9.7%). The odds of receiving a PrGD was nine times higher in the IG compared to conventional care. 42% of diagnosed infants would have been missed using conventional NICU protocols (69% of whom were non-white) , highlighting the limitations of current diagnostic approaches and the correlated inequity of care. 24% of diagnosed infants were not suspected of having a genetic condition based on EMR review and would not have been offered testing under standard care protocols. By using simple, broad exclusion criteria, the diagnostic yield and access to testing were comparable across racial groups, with significantly more non-white and Black infants receiving a PrGD than through conventional care, effectively mitigating racial disparities. Access to a PrGD led to a change in clinical management for nearly 97% of diagnosed infants , influencing medical consultations, additional testing, medication adjustments and family health implications. “With today’s reliable and rapid genomic technology, we can now deliver answers in days. More importantly, we finally have clear, simple criteria to guide neonatologists in determining which infants should receive genomic screening in the NICU,” said Paul Kruszka, MD, FACMG, Chief Medical Officer at GeneDx. “There is an urgent need to make rapid genome sequencing (rGS) a standard part of NICU care to prevent missed diagnoses and ensure every infant gets the critical care they deserve. By expanding access, we can dramatically improve early detection of genetic conditions, enabling timely interventions and driving more equitable care for all infants.” GeneDx is a proud collaborator of SeqFirst and their on-going research, as the clinical lab behind both the Seqfirst-neo and SeqFirst Developmental Differences (DDi) projects. Seqfirst-neo focuses on evaluating whether a genotype-driven workflow, using broad and simple exclusion criteria for eligibility, enhances access to a PrGD in critically ill newborns. SeqFirst DDi aims to promote early and equitable access to PrGD for children with atypical development by offering genome sequencing at the time of presentation, rather than after a traditional staged evaluation and testing process. Accelerating care in the NICU: GeneDx recently announced ultraRapid Whole Genome Sequencing, offering accelerated and comprehensive genomic insights for neonatal and pediatric patients in the NICU and PICU in as soon as 48 hours. As part of the company’s commitment to increasing access to genomic testing, GeneDx also recently integrated with Epic Aura, enabling health systems to deliver fast and accurate genetic diagnoses to patients and accelerate the path to treatment. By driving collaborative research that informs utilization protocols, continuing to decrease turnaround times, and expanding access to testing, more patients can benefit from GeneDx’s genomic insights of over 750,000 exomes and genomes and increase the likelihood of obtaining definitive diagnoses. About GeneDx: At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. For more information, please visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram.

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024 PARIS, FRANCE, 18 November, 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today announced data at the American Association for the Study of Liver Diseases (AASLD) assessing the long-term efficacy and safety of patients treated with Bylvay® from two Phase III open-label extension studies: late-breaking abstract (#5045) on PEDFIC 2 in Progressive Familial Intrahepatic Cholestasis (PFIC) and oral presentation ASSERT-EXT (#50) in Alagille syndrome (ALGS). Sustained efficacy data and improvements in height, weight and sleep measures were observed for patients treated with Bylvay for at least 72 weeks in both rare cholestatic diseases. “We know from our work with patient communities that receiving a diagnosis of PFIC and ALGS can be overwhelming in a patient or caregivers’ life. Disease symptoms like severe itch can have an impact on the whole family,” said Sandra Silvestri, EVP Chief Medical Officer, Ipsen. “Data suggesting Bylvay-treated patients experienced sustained efficacy, and which support the safety and tolerability profile seen in previous clinical trials, are important. Ipsen is committed to being the leader across rare cholestatic liver diseases and we are just getting started.” PEDFIC 2 Study in PFIC “These open-label extension data from PEDFIC 2 suggest that the initial reduction in pruritus and in serum bile acid levels achieved following initiation of odevixibat are being sustained into the longer term,” said Dr. Richard J. Thompson, Professor of Molecular Hepatology, King’s College London and principal investigator of the PEDFIC 2 trial. “We are also observing reductions in both pruritus and serum bile acid across a number of PFIC subtypes. This is important information for our understanding of the therapeutic management of our patients living with PFIC.” PEDFIC 2 was an open-label extension study (n=116; patients from PEDFIC 1 Bylvay and placebo cohorts at week 24, and new Bylvay-naïve patients of any age and PFIC subtype), evaluating the efficacy and safety of Bylvay through 72 weeks (n=83).1 The data showed a clinically meaningful 1-point reduction in pruritus score at week 72 in 42 percent of patients <18 years old with PFIC 1 and 2 who transitioned to Bylvay at 24 weeks (n=5/12) and 61 percent of patients with any type of PFIC and of any age excluding episodic (n=19/31). Rapid initial pruritus scores achieved by week 4 were sustained for patients who remained on treatment. At 72 weeks, the mean change in serum bile acid (sBA) levels from patients who transition to Bylvay at week 24 (n=15) was –104.00 µmol/L and Bylvay-treated patients (n=43) was -57.97 µmol/L . Beyond the clinically meaningful and sustained improvements seen in pruritus and sBA levels, height, weight and sleep increases were reported at 72 weeks in Bylvay-treated patients. Most adverse events in Bylvay-treated patients over the duration of the study were reported as mild or moderate. The most common were gastrointestinal (17.2 percent; n=20/116), including diarrhea (12 percent; n=14/116). In two cases, diarrhea led to one treatment interruption and one discontinuation. Assert-EXT Study in ALGS“The sustained improvements we've seen in Bylvay-treated individuals living with Alagille syndrome are encouraging,” said Dr. Nadia Ovchinsky, Chief, Division of Gastroenterology and Hepatology, Hassenfeld Children's Hospital at NYU Langone, New York. and principal investigator of the ASSERT trial. “These results not only show the potential to manage symptoms like pruritus, which can be extremely difficult for children and their parents to manage, but we’re also seeing a consistent safety profile over the longer term with sustained tolerability.” In ASSERT-EXT, the open-label extension study (n=50) evaluating the long-term efficacy and safety of Bylvay in ALGS patients (ages 1-15.9 years) through 72 weeks (n=44), sustained improvements were observed in pruritus and sBA levels through 72 weeks.2 At week 72, 93 percent (n=28/30) of patients who received Bylvay throughout the 24 weeks ASSERT trial and 77 percent (n=10/13) of those who transitioned from placebo to Bylvay at week 24 experienced a clinically meaningful ≥1 point reduction in pruritus score. Reductions in sBA levels were also observed in patients treated with Bylvay for 72 weeks showing a mean reduction of 124 µmol/L in those who continuously received Bylvay and a mean reduction of 139 µmol/L in patients who transitioned from placebo to Bylvay. Mean changes from baseline were observed in height (8.2 cm) and weight (2.8 kg) on continuous Bylvay use and for patients who transitioned from placebo to Bylvay, height (10.7 cm) and weight (3.3 kg) mean changes were also reported. Improvements in sleep were observed from weeks 24 to 72 across all four sleep parameters (n=43), including proportion of days seeing blood due to scratching, proportion of days needing help falling asleep, proportion of days needing soothing and daytime tiredness. Data supports the safety profile in the ASSERT clinical trial for Bylvay. Treatment emergent adverse event (TEAE) occurred in 18 percent (n=6/33) of patients who continuously received Bylvay and 41 percent (n=7/17) of patients who transitioned from placebo to Bylvay. Most adverse events were mild or moderate with diarrhea as the most common TEAE. One TEAE led to discontinuation. About PFIC and ALGSPFIC is a group of rare genetic disorders in which bile acids build up in the liver, causing damage, which may result in liver failure. ALGS is also a rare genetic disorder, affecting multiple organs including the liver, heart, skeleton, eyes and kidneys. Without early diagnosis and effective management, people living with PFIC and ALGS may need a liver transplant. Debilitating itch, caused as a result of the serum bile acid build up, is one of the most common symptoms of both PFIC and ALGS, significantly impacting sleep and daily activities and resulting in skin mutilation, loss of sleep, irritability, and poor attention. Bylvay (odevixibat) posters presented at AASLD Abstract Poster or Oral # Full title Authors ASSERT-EXT final results Oral, Abstract Parallel, ePoster [50]Monday 18 November 11:45–12:00Human Cholestatic, PBC and other Biliary Disorders in Children and Adults ASSERT-EXT: Final data from an open-label, Phase 3 study of odevixibat in patients with Alagille syndrome Nadia Ovchinsky et al. Hepatic parameters with ODX in PFIC Poster, Abstract [4277]Monday 18 November13:00–14:00Poster Session IV Effects of odevixibat vs placebo on hepatic biochemical parameters and liver adverse events in patients with PFIC: Data from the PEDFIC 1 study Tassos Grammatikopoulos et al. Phase I DDI results Poster, Abstract [4280]Monday 18 November13:00–14:00Poster Session IV A Phase 1, open-label, fixed-sequence, crossover study to evaluate the interaction of multiple-dose odevixibat with the pharmacokinetics of single-dose combined oral contraceptive steroids in healthy female participants Florent Mazuir et al. PEDFIC1/2 OLE final results (LB) Poster, Abstract [5045]Monday 18 November13:00–14:00Poster Session IV Sustained, long-term efficacy and safety of odevixibat in patients with progressive familial intrahepatic cholestasis: Results from the PEDFIC2 Phase 3, open-label extension study Richard Thompson et al. About Bylvay (odevixibat)Odevixibat is a once-daily non-systemic ileal bile acid transport (IBAT) inhibitor approved under the brand name Bylvay® in the U.S. as the first drug treatment option for patients 3 months of age and older living with cholestatic pruritus due to progressive familial intrahepatic cholestasis (PFIC). BYLVAY may not be effective in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of the bile salt export pump protein. Odevixibat was also approved in June 2021 in the E.U. under the brand name Bylvay®, as the first drug treatment option for all types of PFIC in patients aged 6 months or older. Bylvay has received orphan exclusivity for the treatment of PFIC in the U.S. and E.U. In June 2023 Bylvay was approved in the U.S. for the treatment of cholestatic pruritus in patients from 12 months of age with Alagille syndrome (ALGS) and received orphan exclusivity for ALGS. In September 2024, odevixibat was approved in the E.U under the brand name Kayfanda® for the treatment of cholestatic pruritus in ALGS in patients aged 6 months or older. IMPORTANT SAFETY INFORMATION – U.S.Warnings and Precautions: Liver Test AbnormalitiesPatients who enrolled in PFIC and ALGS clinical trials had abnormal liver tests at baseline. In clinical trials, treatment-emergent elevations of liver tests or worsening of liver tests relative to baseline values were observed. Most abnormalities included elevations in aspartate aminotransferase (AST), alanine transaminase (ALT) in PFIC and ALGS, and total and direct bilirubin in PFIC clinical trials. No patients permanently discontinued treatment due to liver test abnormalities. Obtain baseline liver tests and monitor during treatment. Dose reduction or treatment interruption may be required if abnormalities occur. For persistent or recurrent liver test abnormalities, consider treatment discontinuation. Permanently discontinue Bylvay if a patient progresses to portal hypertension or experiences a hepatic decompensation event. DiarrheaDiarrhea occurred in both PFIC and ALGS clinical trials in BYLVAY-treated patients at a rate greater than placebo treated patients. If diarrhea occurs with use of BYLVAY, monitor for dehydration and treat promptly. Treatment interruption or discontinuation may be required for persistent diarrhea with no alternate etiology. Fat-Soluble Vitamin (FSV) DeficiencyFat-soluble vitamins (FSV) include vitamin A, D, E, and K. PFIC and ALGS patients can have FSV deficiency at baseline, as part of their disease. BYLVAY may affect absorption of fat-soluble vitamins. Obtain baseline levels and monitor during treatment, along with any clinical manifestations. Supplement if deficiency is observed. If FSV deficiency persists or worsens despite FSV supplementation, discontinue treatment. ADVERSE REACTIONSALGS: The most common adverse reactions (>5%) are diarrhea, abdominal pain, hematoma, and decreased weight.PFIC: The most common adverse reactions (>2%) are diarrhea, liver test abnormalities, vomiting, abdominal pain, and fat-soluble vitamin deficiency. DRUG INTERACTIONSFor patients taking bile acid binding resins, take BYLVAY at least 4 hours before or 4 hours after administering, as bile acid binding resins may bind to and reduce BYLVAY efficacy. USE IN SPECIFIC POPULATIONSThere are no human data on BYLVAY use in pregnant persons to establish a drug-associated risk of major birth defects, miscarriage, or adverse developmental outcomes. Based on findings from animal reproduction studies, BYLVAY may cause cardiac malformations when a fetus is exposed during pregnancy. There is a pregnancy safety study that monitors pregnancy outcomes in women exposed to BYLVAY during pregnancy. Pregnant women exposed to BYLVAY, or their healthcare providers, should report BYLVAY exposure by calling 1-855-463-5127. To report SUSPECTED ADVERSE REACTIONS, contact Ipsen Biopharmaceuticals, Inc. at +1-855-463-5127, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Indications and Usage U.S.Bylvay is an ileal bile acid transporter (IBAT) inhibitor indicated for the treatment of cholestatic pruritus in:Patients 12 months of age and older with Alagille syndrome (ALGS)Patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC) Limitation of useBylvay may not be effective in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of the bile salt export pump protein Please see full U.S. Prescribing Information. Indications of use E.U.Bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged 6 months or older. Please see full E.U. Prescribing Information. Kayfanda is indicated for the treatment of cholestatic pruritus in Alagille syndrome (ALGS) in patients aged 6 months or older. Please see full E.U. Prescribing Information. ENDS About PEDFIC 1 and 2PEDFIC 1 was a 24-week double-blind, randomized, placebo-controlled trial that evaluated the efficacy and tolerability of two doses of odevixibat in reducing pruritus and serum bile acid levels in children with PFIC 1 or 2. PEDFIC 2 is a 72-week open label extension trial, which consisted of children from PEDFIC 1 who received either Bylvay (cohort 1a) or placebo (cohort 1b) and a new cohort (2) of Bylvay-naïve patients of any age and PFIC subtype. PEDFIC is the largest, global, Phase III trial ever conducted in PFIC. PEDFIC 1 (NCT03566238) was a 24-week double-blind, randomized (1:1:1), placebo-controlled trial that evaluated the efficacy and tolerability of two doses of odevixibat in reducing pruritus and serum bile acid levels in children with PFIC 1 or 2. Participants were randomly allocated to receive placebo (n=20), odevixibat 40 μg/kg (n=23), or odevixibat 120 μg/kg (n=19) once a day. The results were published in The Lancet.3 PEDFIC 2 (NCT03659916), an open-label extension of PEDFIC 1, is a 72-week trial that aimed to evaluate the efficacy and tolerability of odevixibat 120 µg/kg once a day in patients with PFIC. Patients were divided into two cohorts: Cohort 1 (n=56) which consisted of children with PFIC 1 or 2 from PEDFIC 1 who received odevixibat (Cohort 1a: n= 37) or placebo (Cohort 1b: n=19), respectively, and Cohort 2 (n=60) which consisted of newly enrolled, odevixibat-naïve patients of any age and PFIC subtype. Interim results were published in The Journal of Hepatology.4 About ASSERT and ASSERT-EXTASSERT (NCT04674761) was a 24-week double-blind, randomized, placebo-controlled trial with an open-label long term extension. ASSERT evaluated the safety and efficacy of 120 µg /kg once-daily odevixibat vs placebo for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). The trial enrolled 52 patients of any age with a genetically confirmed diagnosis of ALGS. The results were published in The Lancet.5 In ASSERT-EXT (NCT05035030), ASSERT’s ongoing open-label extension, all trial participants received 120 μg/kg of odevixibat once daily for 72-weeks after the double-blind treatment period completed. In both ASSERT and ASSERT-EXT, the investigators looked for changes in pruritus, serum bile acid concentrations, sleep, and treatment-emergent adverse events. About IpsenWe are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 80 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com Ipsen Media contacts Investors Nicolas Bogler | + 33 6 52 19 98 92 Media Jennifer Smith-Parker | + 44 7487 75 71 00 | jennifer.smith-parker.ext@ipsen.comRachel Reiff | + 1 908 616 1680 | rachel.reiff@ipsen.comAnna Gibbins | + 44 7717 80 19 00 | anna.gibbins@ipsen.com Disclaimers and/or Forward-Looking Statements Ipsen The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen’s activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen’s partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen’s business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen’s latest Universal Registration Document, available on ipsen.com. References 1Thompson RJ, et al. Sustained, long-term efficacy and safety of odevixibat in patients with progressive familial intrahepatic cholestasis: Results from the PEDFIC2 phase 3, open-label extension study. Poster Abstract 5045, American Association for the Study of Liver Disease (AASLD). 20242 Ovchinsky N., et al. ASSERT-EXT: Final data from an open-label, phase 3 study of odevixibat in patients with Alagille syndrome. Oral abstract Parallel ePoster 50. American Association for the Study of Liver Disease (AASLD). 20243 Thompson RJ, et al. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2022. 7:830–842.4 Thompson RJ, et al. Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis 2023. JHEP Rep. 5(8):100782.5 Ovchinsky N., et al. Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT); a phase 3, double-blind, randomized, placebo-controlled trial. Lancet Gastroenterol / Hepatol. 2024 doi.org/10.1016/S2468-1253(24)00074-8. Attachment Ipsen PR_Bylvay® (odevixibat) data shows sustained improvement in severe itch and sBA in PFIC and ALGS_181124